| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 41 | 2023 | 5767 | 1.470 |
Why?
|
| Prostatectomy | 22 | 2023 | 962 | 0.940 |
Why?
|
| Cryosurgery | 1 | 2019 | 167 | 0.630 |
Why?
|
| Cystectomy | 2 | 2018 | 623 | 0.510 |
Why?
|
| Urinary Diversion | 1 | 2015 | 69 | 0.490 |
Why?
|
| Prostate-Specific Antigen | 11 | 2023 | 993 | 0.440 |
Why?
|
| Prostate | 11 | 2023 | 1088 | 0.400 |
Why?
|
| Urinary Incontinence | 2 | 2014 | 149 | 0.380 |
Why?
|
| Robotic Surgical Procedures | 5 | 2018 | 481 | 0.370 |
Why?
|
| Genetic Therapy | 8 | 2011 | 1616 | 0.280 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 3 | 2014 | 84 | 0.260 |
Why?
|
| Muscarinic Antagonists | 2 | 2016 | 83 | 0.250 |
Why?
|
| Robotics | 2 | 2023 | 359 | 0.250 |
Why?
|
| Carcinosarcoma | 1 | 2005 | 146 | 0.240 |
Why?
|
| Behavior Therapy | 1 | 2006 | 298 | 0.230 |
Why?
|
| Virtual Reality | 1 | 2023 | 34 | 0.230 |
Why?
|
| Succinic Acid | 1 | 2022 | 23 | 0.220 |
Why?
|
| Carcinoma, Ductal | 2 | 2014 | 145 | 0.220 |
Why?
|
| Incidental Findings | 2 | 2012 | 272 | 0.220 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2003 | 73 | 0.220 |
Why?
|
| Male | 51 | 2023 | 123000 | 0.210 |
Why?
|
| Unnecessary Procedures | 1 | 2003 | 104 | 0.210 |
Why?
|
| Ribs | 1 | 2003 | 91 | 0.210 |
Why?
|
| Urethral Diseases | 1 | 2002 | 36 | 0.210 |
Why?
|
| Diverticulum | 1 | 2002 | 35 | 0.210 |
Why?
|
| Urethral Neoplasms | 1 | 2002 | 60 | 0.210 |
Why?
|
| Thymidine Kinase | 4 | 2006 | 193 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2023 | 2326 | 0.190 |
Why?
|
| Solifenacin Succinate | 2 | 2016 | 3 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2016 | 716 | 0.170 |
Why?
|
| Health Facilities | 1 | 2019 | 79 | 0.170 |
Why?
|
| Neurogenesis | 2 | 2013 | 238 | 0.170 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 3022 | 0.170 |
Why?
|
| Seminal Vesicles | 3 | 2014 | 152 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 335 | 0.160 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 1046 | 0.160 |
Why?
|
| Denervation | 1 | 2017 | 33 | 0.160 |
Why?
|
| Humans | 55 | 2023 | 261506 | 0.150 |
Why?
|
| Neoplasm Metastasis | 5 | 2005 | 5112 | 0.150 |
Why?
|
| Middle Aged | 35 | 2023 | 86204 | 0.150 |
Why?
|
| Biopsy, Needle | 4 | 2007 | 1363 | 0.150 |
Why?
|
| Caveolin 1 | 3 | 2007 | 204 | 0.150 |
Why?
|
| Adenocarcinoma | 4 | 2015 | 7789 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2020 | 627 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 383 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 3981 | 0.140 |
Why?
|
| Semaphorins | 2 | 2013 | 38 | 0.140 |
Why?
|
| Postoperative Complications | 5 | 2023 | 5542 | 0.140 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 28 | 0.140 |
Why?
|
| Nerve Growth Factor | 1 | 2016 | 45 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2016 | 1270 | 0.140 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2016 | 43 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 500 | 0.130 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 112 | 0.130 |
Why?
|
| Cystostomy | 1 | 2015 | 13 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 1491 | 0.130 |
Why?
|
| Stromal Cells | 2 | 2017 | 825 | 0.130 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2017 | 185 | 0.130 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2014 | 24 | 0.130 |
Why?
|
| Carcinoma, Large Cell | 1 | 2014 | 94 | 0.120 |
Why?
|
| Penile Erection | 3 | 2010 | 86 | 0.120 |
Why?
|
| Quinuclidines | 1 | 2014 | 48 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 787 | 0.120 |
Why?
|
| Ileum | 1 | 2015 | 165 | 0.120 |
Why?
|
| Operative Time | 1 | 2015 | 217 | 0.120 |
Why?
|
| Acyclovir | 2 | 2004 | 78 | 0.120 |
Why?
|
| Neuroepithelial Cells | 1 | 2013 | 13 | 0.120 |
Why?
|
| Simulation Training | 1 | 2016 | 149 | 0.120 |
Why?
|
| Cognition | 1 | 2020 | 968 | 0.120 |
Why?
|
| Creatinine | 1 | 2016 | 531 | 0.120 |
Why?
|
| Valine | 2 | 2004 | 176 | 0.120 |
Why?
|
| Neoplasm Grading | 5 | 2017 | 1742 | 0.120 |
Why?
|
| Biopsy | 7 | 2023 | 3443 | 0.120 |
Why?
|
| Aged | 26 | 2020 | 70117 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2015 | 195 | 0.110 |
Why?
|
| Ureter | 1 | 2015 | 209 | 0.110 |
Why?
|
| Surgeons | 1 | 2020 | 519 | 0.110 |
Why?
|
| Carcinoma | 2 | 2017 | 2578 | 0.110 |
Why?
|
| Veterans | 1 | 2003 | 1641 | 0.110 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 25 | 0.100 |
Why?
|
| Collagen | 1 | 2015 | 752 | 0.100 |
Why?
|
| Urologic Surgical Procedures | 1 | 2011 | 93 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2014 | 13658 | 0.100 |
Why?
|
| Time Factors | 7 | 2015 | 12926 | 0.100 |
Why?
|
| Colon | 1 | 2015 | 670 | 0.100 |
Why?
|
| Impotence, Vasculogenic | 1 | 2010 | 11 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 205 | 0.100 |
Why?
|
| Ganciclovir | 3 | 2006 | 174 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 487 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 441 | 0.090 |
Why?
|
| Biomarkers, Tumor | 7 | 2015 | 10331 | 0.090 |
Why?
|
| Urology | 1 | 2011 | 128 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 2576 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 5539 | 0.090 |
Why?
|
| Antibody Formation | 1 | 2011 | 383 | 0.090 |
Why?
|
| Adult | 18 | 2023 | 77950 | 0.090 |
Why?
|
| Hypogonadism | 1 | 2013 | 257 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 674 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 1021 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2015 | 32848 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2014 | 829 | 0.080 |
Why?
|
| Testosterone | 1 | 2013 | 619 | 0.080 |
Why?
|
| Computer-Assisted Instruction | 1 | 2008 | 81 | 0.080 |
Why?
|
| Simplexvirus | 3 | 2006 | 159 | 0.080 |
Why?
|
| Sural Nerve | 1 | 2007 | 54 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2011 | 1529 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2012 | 691 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2008 | 362 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2016 | 1823 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 411 | 0.070 |
Why?
|
| Penis | 1 | 2007 | 123 | 0.070 |
Why?
|
| Selenomethionine | 1 | 2006 | 41 | 0.070 |
Why?
|
| ROC Curve | 3 | 2023 | 1183 | 0.070 |
Why?
|
| Selenium | 1 | 2006 | 47 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2010 | 667 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 5437 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 2341 | 0.070 |
Why?
|
| Pyrazines | 1 | 2008 | 495 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2013 | 2819 | 0.070 |
Why?
|
| Antiviral Agents | 4 | 2006 | 1230 | 0.070 |
Why?
|
| Neurons | 1 | 2016 | 2287 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2023 | 37905 | 0.060 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 14889 | 0.060 |
Why?
|
| Patient Participation | 1 | 2008 | 446 | 0.060 |
Why?
|
| Nephrectomy | 2 | 2023 | 779 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2011 | 1000 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 60 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 748 | 0.060 |
Why?
|
| Electron Transport Complex II | 1 | 2022 | 5 | 0.060 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 210 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 622 | 0.060 |
Why?
|
| Surveys and Questionnaires | 4 | 2010 | 5687 | 0.060 |
Why?
|
| Electron Transport | 1 | 2022 | 79 | 0.060 |
Why?
|
| Citrates | 1 | 2022 | 39 | 0.050 |
Why?
|
| Ubiquinone | 1 | 2022 | 37 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 89 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 62 | 0.050 |
Why?
|
| Caveolins | 1 | 2002 | 73 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2008 | 1555 | 0.050 |
Why?
|
| Zinc | 1 | 2022 | 188 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 397 | 0.050 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 7548 | 0.050 |
Why?
|
| Incidence | 2 | 2020 | 5673 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2017 | 760 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 660 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2023 | 12873 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 29902 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2054 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2023 | 9244 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2011 | 1375 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 1547 | 0.050 |
Why?
|
| Adenoviridae | 4 | 2011 | 1459 | 0.050 |
Why?
|
| Leuprolide | 2 | 2014 | 65 | 0.050 |
Why?
|
| Disease Progression | 3 | 2017 | 6682 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 1509 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3230 | 0.040 |
Why?
|
| Pedigree | 1 | 2003 | 1890 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 4892 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 4744 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2004 | 1688 | 0.040 |
Why?
|
| Prognosis | 5 | 2023 | 21713 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 902 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 657 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1064 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2018 | 155 | 0.040 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2017 | 20 | 0.040 |
Why?
|
| Prodrugs | 3 | 2004 | 217 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 987 | 0.040 |
Why?
|
| Genetic Vectors | 3 | 2011 | 1694 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2017 | 1987 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2004 | 1586 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 2864 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 1085 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2023 | 851 | 0.030 |
Why?
|
| Prevalence | 1 | 2003 | 3260 | 0.030 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2014 | 10 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 4844 | 0.030 |
Why?
|
| Quality of Life | 2 | 2006 | 4532 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 10001 | 0.030 |
Why?
|
| Ejaculatory Ducts | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2014 | 88 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 3 | 2014 | 4975 | 0.030 |
Why?
|
| United States | 2 | 2020 | 15433 | 0.030 |
Why?
|
| Female | 7 | 2023 | 141928 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2013 | 1549 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2010 | 10035 | 0.030 |
Why?
|
| Kallikreins | 1 | 2014 | 84 | 0.030 |
Why?
|
| Apoptosis | 4 | 2013 | 7591 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 5395 | 0.030 |
Why?
|
| Hematocrit | 1 | 2013 | 142 | 0.030 |
Why?
|
| Pelvis | 1 | 2014 | 362 | 0.030 |
Why?
|
| Etoposide | 1 | 2014 | 870 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2023 | 3341 | 0.030 |
Why?
|
| Risk Factors | 2 | 2023 | 17523 | 0.030 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 8865 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2006 | 4971 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2017 | 992 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2023 | 9180 | 0.020 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 14551 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 477 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 878 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 980 | 0.020 |
Why?
|
| Alprostadil | 1 | 2010 | 33 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5377 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2594 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 2315 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 2218 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 243 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 224 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 219 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 261 | 0.020 |
Why?
|
| Tape Recording | 1 | 2008 | 14 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 402 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 54 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 665 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 2588 | 0.020 |
Why?
|
| Pamphlets | 1 | 2008 | 31 | 0.020 |
Why?
|
| Animals | 6 | 2017 | 59536 | 0.020 |
Why?
|
| Multimedia | 1 | 2008 | 25 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2013 | 7226 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 716 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 2944 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2008 | 159 | 0.020 |
Why?
|
| Television | 1 | 2008 | 74 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 14289 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 1033 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 7551 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.020 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2007 | 43 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.020 |
Why?
|
| Educational Status | 1 | 2008 | 397 | 0.020 |
Why?
|
| Health Status | 1 | 2010 | 590 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1972 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 1959 | 0.020 |
Why?
|
| Bortezomib | 1 | 2008 | 543 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 3890 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 4298 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 39 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2008 | 298 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2008 | 383 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 272 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 726 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 209 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 2466 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2014 | 1225 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 3719 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 904 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2004 | 3842 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 2316 | 0.020 |
Why?
|
| Informed Consent | 1 | 2008 | 419 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2139 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 1764 | 0.020 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2004 | 41 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7222 | 0.020 |
Why?
|
| Flutamide | 1 | 2004 | 40 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 875 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 1408 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6207 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 2307 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2004 | 275 | 0.010 |
Why?
|
| Kidney | 1 | 2012 | 2146 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 3441 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 665 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 604 | 0.010 |
Why?
|
| Nucleoside Deaminases | 1 | 2002 | 33 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 2002 | 39 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2008 | 3536 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2008 | 787 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3639 | 0.010 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 81 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2008 | 3033 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 1058 | 0.010 |
Why?
|
| Cytokines | 1 | 2011 | 2809 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 21445 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2004 | 411 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 1048 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 34495 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 3472 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 15862 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 838 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 31252 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2002 | 577 | 0.010 |
Why?
|
| Recurrence | 1 | 2007 | 4758 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 840 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 4938 | 0.010 |
Why?
|
| Bacteria | 1 | 2002 | 611 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8873 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 697 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 6942 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 11538 | 0.000 |
Why?
|